US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TuHURA Biosciences, Inc.

2.81

-0.0800-2.77%

Post-market: 2.810.00000.00%19:32 EDT

Volume:70.89K

Turnover:201.26K

Market Cap:122.74M

PE:-3.04

High:2.94

Open:2.91

Low:2.70

Close:2.89

Loading ...

Overview Company News Filings

Tuhura Biosciences, Inc. Appoints DR. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

THOMSON REUTERS

Press Release: TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

TuHURA Biosciences Is Maintained at Buy by HC Wainwright & Co.

TuHURA Biosciences price target lowered to $12 from $13 at H.C. Wainwright

TuHURA Biosciences FY24 EPS ($1.21) Up From ($2.47) YoY

Press Release: TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

TuHURA Biosciences appoints Craig Tendler to board of directors

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors

ACCESS Newswire

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

ACCESS Newswire

TuHURA Biosciences Initiated at Buy by HC Wainwright & Co.

HC Wainwright Initiates TuHURA Biosciences at Buy With $13 Price Target

MT Newswires Live

TuHURA Biosciences initiated with a Buy at H.C. Wainwright

Tuhura Biosciences, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS

TuHURA Biosciences Inc expected to post a loss of 13 cents a share - Earnings Preview

HURA: Initiating an Immune Response

Zacks Small Cap Research

When Will TuHURA Biosciences, Inc. (NASDAQ:HURA) Turn A Profit?

Simply Wall St.

When Can We Expect A Profit From TuHURA Biosciences, Inc. (NASDAQ:HURA)?

Simply Wall St.

TuHURA Biosciences Initiated at Buy by Rodman & Renshaw

TuHURA Biosciences initiated with a Buy at Rodman & Renshaw

TuHura Biosciences Agrees to Acquire Kineta in Cash-and-Stock Deal

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/HURA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HURA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":2.81,"timestamp":1749240000000,"preClose":2.89,"halted":0,"volume":70892,"hourTrading":{"tag":"盘后","latestPrice":2.81,"preClose":2.81,"latestTime":"19:32 EDT","volume":40,"amount":112.84,"timestamp":1749252743510},"delay":0,"floatShares":21286907,"shares":43680396,"eps":-0.924572,"marketStatus":"Market Closed","change":-0.08,"latestTime":"06-06 16:00:00 EDT","open":2.91,"high":2.9415,"low":2.7,"amount":201260.3746672,"amplitude":0.083564,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.924572,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":2.89,"preHourTrading":{"tag":"盘前","latestPrice":2.89,"preClose":2.89,"latestTime":"09:22 EDT","volume":593,"amount":1782.4699395,"timestamp":1749216125786},"postHourTrading":{"tag":"盘后","latestPrice":2.81,"preClose":2.81,"latestTime":"19:32 EDT","volume":40,"amount":112.84,"timestamp":1749252743510},"volumeRatio":0.4762154266298755},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","floatShares":21286907,"roa":"-90.68%","roe":"-332.67%","lyrEps":-1.213628,"volumeRatio":0.4762154266298755,"shares":43680396,"dividePrice":0,"high":2.9415,"amplitude":0.083564,"preClose":2.89,"low":2.7,"week52Low":1.8,"pbRate":"12.82","week52High":13.125,"institutionHeld":0,"latestPrice":2.81,"eps":-0.924572,"divideRate":0,"volume":70892,"delay":0,"ttmEps":-0.924572,"open":2.91,"prevYearClose":4.09,"prevWeekClose":3.06,"prevMonthClose":3.06,"prevQuarterClose":3.23,"fiveDayClose":3.06,"twentyDayClose":3.93,"sixtyDayClose":2.1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HURA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525010550","title":"Tuhura Biosciences, Inc. Appoints DR. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2525010550","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525010550?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:24","pubTimestamp":1744028658,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nTUA19NJVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2525010694","title":"Press Release: TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2525010694","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525010694?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:24","pubTimestamp":1744028640,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management. Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical/clinical candidates and 7 investigational new drug / clinical trial applications. Extensive knowledge in the biochemistry and pharmacology of the Delta Opioid Receptor , the primary target in TuHURA's Antibody Drug Conjugate  and Antibody Peptide Conjugate  technology platform. TAMPA, Fla., April 7, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the appointment of Bertrand Le Bourdonnec, PhD as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management.Dr. Le Bourdonnec added, \"I am thrilled to join the TuHURA team at this pivotal time in the Company's evolut","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","IE00BLSP4452.SGD","LU1066051498.USD","BK4581","LU2456880835.USD","IE000M9KFDE8.USD","APC","BK4599","LU2420271590.USD","SG9999002224.SGD","LU0225284248.USD","LU0058720904.USD","SG9999013999.USD","LU0157215616.USD","LU0170899867.USD","LU2237443549.SGD","LU0289739699.SGD","LU2236285917.USD","SGXZ57979304.SGD","BK4585","SG9999002232.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0077335932.USD","SG9999001176.USD","BK4080","LU0321505868.SGD","LU1366333091.USD","LU1366192091.USD","R","BK4231","IE00BLSP4239.USD","LU2237443622.USD","LU2417539215.USD","LU1894683348.USD","BK4533","LU1066053197.SGD","ADC","LU2237443978.SGD","LU0456855351.SGD","SG9999003800.SGD","LU0306806265.USD","HURA","LU1883839398.USD","LU0234572021.USD","LU1894683264.USD","BK4588","LU0122379950.USD","LU0868494617.USD"],"gpt_icon":1},{"id":"2524554482","title":"TuHURA Biosciences Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524554482","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524554482?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:58","pubTimestamp":1743681480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2025 07:58 ET (11:58 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA"],"gpt_icon":0},{"id":"2524234995","title":"TuHURA Biosciences price target lowered to $12 from $13 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2524234995","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524234995?lang=en_us&edition=fundamental","pubTime":"2025-04-03 18:15","pubTimestamp":1743675321,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on TuHURA Biosciences (HURA) to $12 from $13 and keeps a Buy rating on the shares following the Q4 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-price-target-lowered-to-12-from-13-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-price-target-lowered-to-12-from-13-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2524187561","title":"TuHURA Biosciences FY24 EPS ($1.21) Up From ($2.47) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2524187561","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524187561?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:13","pubTimestamp":1743509636,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences FY24 EPS ($1.21) Up From ($2.47) YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44583503/tuhura-biosciences-fy24-eps-1-21-up-from-2-47-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA"],"gpt_icon":0},{"id":"2524190796","title":"Press Release: TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2524190796","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524190796?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:00","pubTimestamp":1743508800,"startTime":"0","endTime":"0","summary":"Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda. MCC Phase 3 trial to be conducted under Special Protocol Assessment . Acquisition of Kineta's Phase 2 ready, VISTA inhibiting antibody targeted for. TAMPA, Fla., April 1, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided financial results for fiscal year 2024 and provided a corporate update.Innate Immune Agonists: TuHURA's IFx technology utilizes a proprietary plasmid DNA or messenger RNA  which, when introduced into or targeted to a tumor, results in the expression of a highly immunogenic gra","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0208291251.USD","LU1069347547.HKD","IE00B2B36J28.USD","LU0266013472.USD","LU1066051225.USD","USJW.SI","IE00B12V2V27.USD","LU2039709279.SGD","LU2112291526.USD","USAW.SI","LU0265550359.USD","R","SG9999013999.USD","BK4516","LU1061106388.HKD","BK4588","BK4534","IE000M9KFDE8.USD",".IXIC","BK4526","BK4509","MRK","SQQQ","IE00BYQNZ168.SGD","LU1917777945.USD","PSQ","BK4232","LU1934455194.USD","SG9999011746.SGD","LU0106261372.USD","QID","QLD","BK4531","TQQQ","MNQmain","TME","SG9999015358.SGD","NVIW.SI","LU0265550946.USD","IE00BN8TJ469.HKD","PFS","TSYW.SI","NQmain","HURA","LU1066051498.USD","LU1571399168.USD","01698","LU1929549753.HKD","IE00BSNM7G36.USD"],"gpt_icon":1},{"id":"2518254745","title":"TuHURA Biosciences appoints Craig Tendler to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2518254745","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518254745?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:30","pubTimestamp":1741696254,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences (HURA) has appointed Craig Tendler, M.D. to its Board of Directors effective March 10, 2025. During his tenure at Johnson & John...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-appoints-craig-tendler-to-board-of-directors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-appoints-craig-tendler-to-board-of-directors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2518749844","title":"TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2518749844","media":"ACCESS Newswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518749844?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:05","pubTimestamp":1741694700,"startTime":"0","endTime":"0","summary":"Dr. Tendler oversaw 30 Major Drug Approvals, including worldwide approvals for J&J's transformational treatments in hematologic malignancies, prostate, lung and bladder cancers. Dr. Tendler also oversaw 13 FDA Breakthrough Designations accelerating the early development of promising investigational medicines intended for treatment of serious oncology indications. TAMPA, FL / ACCESS Newswire / March 11, 2025 / TuHURA Biosciences, Inc.  , a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced it has appointed Craig L. Tendler, M.D. to its Board of Directors effective March 10, 2025.Dr. Tendler added, \"TuHURA has established a science-based portfolio of novel complementary technologies and late-stage drug candidates that I believe has the potential to make a significant impact on the immuno-oncology treatment landscape. The data demonstrated to date are promising and underscore the ability of one o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tuhura-biosciences-inc-appoints-craig-120500961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4531","BK4571","JNJ","GMRE","BK4563","BK4565","BK4139","LU2039709279.SGD","BK4548","BK4526","HURA","LU1023057109.AUD","BK4225","BK4203","01698","BK4108","LU0359201612.USD","BK4535","LU0359202008.SGD","IE00B12V2V27.USD","IE00BYTNYN87.SGD","BK4552","BK4509","SG9999011746.SGD","IE00BYQNZ168.SGD","TME"],"gpt_icon":0},{"id":"2518233227","title":"TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2518233227","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518233227?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:00","pubTimestamp":1741611600,"startTime":"0","endTime":"0","summary":"Live webcast fireside chat on Tuesday, March 18th at 8:30 AM PT. TAMPA, FL / ACCESS Newswire / March 10, 2025 / TuHURA Biosciences, Inc.  , a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA, will participate in a fireside chat on Tuesday, March 18, 2025 at 8:30 AM PT at the 37th Annual ROTH Conference being held in Dana Point, CA.In addition to the presentation, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website.TuHURA Biosciences, Inc.  is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cance","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tuhura-biosciences-inc-present-37th-130000429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4552","IE00BYTNYN87.SGD","BK4509","BK4535","01698","TME","LU2039709279.SGD","BK4548","BK4565","LU0359202008.SGD","BK4526","BK4108","HURA","BK4563","ROTH","BK4139","IE00B12V2V27.USD","SG9999011746.SGD","BK4571","LU0359201612.USD","IE00BYQNZ168.SGD","BK4531","LU1023057109.AUD"],"gpt_icon":0},{"id":"2516635440","title":"TuHURA Biosciences Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635440","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635440?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:27","pubTimestamp":1741008420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2025 08:27 ET (13:27 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2516680115","title":"HC Wainwright Initiates TuHURA Biosciences at Buy With $13 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2516680115","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516680115?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:20","pubTimestamp":1741004457,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates TuHURA Biosciences at Buy With $13 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HURA"],"gpt_icon":0},{"id":"2516828386","title":"TuHURA Biosciences initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2516828386","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516828386?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:21","pubTimestamp":1741000864,"startTime":"0","endTime":"0","summary":"H.C. Wainwright initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $13 price target TuHURA is a clinical-stage biotechnology com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2516968469","title":"Tuhura Biosciences, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2516968469","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516968469?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:16","pubTimestamp":1741000560,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nAZN3H7E64:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2510362858","title":"TuHURA Biosciences Inc  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2510362858","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510362858?lang=en_us&edition=fundamental","pubTime":"2025-02-10 19:17","pubTimestamp":1739186229,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc  expected to post a loss of13cents a share - Earnings Preview TuHURA Biosciences Inc HURA.OQ HURA.O is expected to report resultson February 12 (estimated) for the period ending","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nL8N3P10VM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA"],"gpt_icon":0},{"id":"2508638964","title":"HURA: Initiating an Immune Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2508638964","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508638964?lang=en_us&edition=fundamental","pubTime":"2025-02-04 17:16","pubTimestamp":1738660560,"startTime":"0","endTime":"0","summary":"IFx-2.0 is an intratumorally injected plasma DNA  that infects cancer cells to produce bacterial proteins on their surface. These proteins stimulate an innate immune response which destroys cancer cells and subsequently activates an adaptive immune response to overcome resistance. TuHURA has demonstrated safety and proof of concept in several small early-stage trials. To date, the company has completed four Phase I studies. They have shown an overall response rate  for MCC in many subjects. The dose escalation portion of the study established that IFx-2.0 was well-tolerated at all dose levels. Further study evaluated MCC patients who had previously received checkpoint therapy. Results showed that IFx-2.0 may overcome primary resistance to checkpoint inhibitor therapy and may provide support for administering the agent before checkpoint inhibitor therapy to increase response rates.Recent research has shown a correlation between high NPM1 mutations and VISTA expression, particularly in A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hura-initiating-immune-response-091600422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B66KJ199.SGD","BK4006","BK4588","ADC","BK4585","LU2463526074.USD","CRS","CVR","LU2065731478.USD","BK4231","BK4136","IE0031619046.USD","IE00B7SZL793.SGD","BK4139","ORR","IP","BK4161","SPA","HURA","IE00B19Z4B17.USD","BK4080"],"gpt_icon":0},{"id":"2505236862","title":"When Will TuHURA Biosciences, Inc. (NASDAQ:HURA) Turn A Profit?","url":"https://stock-news.laohu8.com/highlight/detail?id=2505236862","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505236862?lang=en_us&edition=fundamental","pubTime":"2025-01-20 21:52","pubTimestamp":1737381162,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse TuHURA Biosciences, Inc.'s ( NASDAQ:HURA ) business as it appears the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hura/tuhura-biosciences/news/when-will-tuhura-biosciences-inc-nasdaqhura-turn-a-profit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":[".IXIC","LU2095319765.USD","NDAQ","BK4112","HURA","NQmain","IE00B64PRP62.GBP","LU2210149790.SGD","MNQmain","IE00B3QW5Z07.USD","USJW.SI","TQQQ","BK4585","USAW.SI","TSYW.SI","QLD","NVIW.SI","SQQQ","IE00BKPKM429.USD","BK4139","QID","LU2210150020.SGD","IE00BGHQF748.EUR","BK4588","PSQ"],"gpt_icon":1},{"id":"2504103637","title":"When Can We Expect A Profit From TuHURA Biosciences, Inc. (NASDAQ:HURA)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2504103637","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504103637?lang=en_us&edition=fundamental","pubTime":"2025-01-18 21:04","pubTimestamp":1737205489,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc.  is possibly approaching a major achievement in its business, so we would like to shine some light on the company. TuHURA Biosciences, Inc. operates as a biotechnology company that develops novel cell and gene therapies based on distinct and synergistic technology platforms. The US$199m market-cap company’s loss lessened since it announced a US$29m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$19m, as it approaches breakeven. As path to profitability is the topic on TuHURA Biosciences' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on TuHURA Biosciences’s board and the CEO’s background.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/expect-profit-tuhura-biosciences-inc-130449262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BKPKM429.USD","USAW.SI","MNQmain","LU2095319765.USD","BK4588","TSYW.SI","IE00BGHQF748.EUR","BK4112","SQQQ","TQQQ","BK4585","NDAQ","BK4139","NVIW.SI",".IXIC","IE00B3QW5Z07.USD","LU2210150020.SGD","USJW.SI","QID","IE00B64PRP62.GBP","NQmain","HURA","QLD","LU2210149790.SGD","PSQ"],"gpt_icon":1},{"id":"2492272581","title":"TuHURA Biosciences Initiated at Buy by Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2492272581","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492272581?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:07","pubTimestamp":1734613620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2024 08:07 ET (13:07 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2492507071","title":"TuHURA Biosciences initiated with a Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2492507071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492507071?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:55","pubTimestamp":1734558913,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $11 price target TuHURA is focused on developing treatments ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-initiated-with-a-buy-at-rodman-renshaw?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-initiated-with-a-buy-at-rodman-renshaw?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2490824403","title":"TuHura Biosciences Agrees to Acquire Kineta in Cash-and-Stock Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2490824403","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490824403?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:51","pubTimestamp":1734015060,"startTime":"0","endTime":"0","summary":"TuHura Biosciences  said Thursday it agreed to acquire Kineta, including the rights to Kineta's KVA12123 checkpoint inhibitor, in a cash-and-stock transaction.Kineta shareholders will receive up to about 3.48 million shares of TuHura stock, subject to a six-month holdback of 869,142 shares for additional liabilities, as well as $9 million in cash less Kineta's working capital deficit at closing and any working capital loans extended by TuHura after the deal was signed, TuHura said.Kineta may also earn payments from potential sale of non-KVA12123 products and technologies prior to the closing of the proposed merger, TuHura added.Meanwhile, TuHura will fund up to $900,000 in KVA12123 clinical trial expenses and may extend $2 million in working capital loans under a clinical trial funding agreement with Kineta, TuHura said, adding $1.75 million of the potential working capital loans will depend on the completion of a financing transaction.The deal is expected to close in Q1 2025, subject ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","HURA"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":45,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HURA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"HURA","fiscalQuarterEnding":"2025/03","expectedEps":-0.13,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2025-03-31","symbol":"HURA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"HURA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-1.37},{"market":"US","date":"2024-10-18","symbol":"HURA","defaultRemindTime":1729258200000,"type":"split","dateTimestamp":1729224000000,"forFactor":35,"toFactor":1,"ratio":35},{"market":"US","date":"2024-10-07","symbol":"HURA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1728273600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HURA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HURA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1747454400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HURA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HURA","date":"2025-06-06","current":-5.370723,"percent":0.906667,"low":-15.284879,"twenty":-10.312959,"median":-8.038111,"eighty":-6.609295,"high":-4.329639,"avg":-8.431799,"sd":2.361164,"marketCap":126236344},"quantilePoints":[{"date":"2024-10-31","current":-8.730961,"twenty":-7.999797,"median":-7.383325,"eighty":-6.996296,"marketCap":255964076},{"date":"2024-11-08","current":-7.555364,"twenty":-8.206244,"median":-7.555364,"eighty":-7.208419,"marketCap":221499291},{"date":"2024-11-15","current":-7.024911,"twenty":-7.675791,"median":-7.239959,"eighty":-7.070789,"marketCap":205948107},{"date":"2024-11-22","current":-7.665321,"twenty":-7.599347,"median":-7.225623,"eighty":-6.910219,"marketCap":140801257},{"date":"2024-11-29","current":-15.010301,"twenty":-7.933971,"median":-7.512354,"eighty":-7.036381,"marketCap":275718282},{"date":"2024-12-06","current":-13.866223,"twenty":-11.098214,"median":-7.555364,"eighty":-7.065054,"marketCap":254703169},{"date":"2024-12-13","current":-12.310277,"twenty":-13.486389,"median":-7.688203,"eighty":-7.082258,"marketCap":226122615},{"date":"2024-12-20","current":-9.152622,"twenty":-13.106555,"median":-8.294564,"eighty":-7.105196,"marketCap":168120904},{"date":"2024-12-27","current":-10.411108,"twenty":-12.712992,"median":-8.730961,"eighty":-7.156808,"marketCap":191237528},{"date":"2025-01-03","current":-9.404319,"twenty":-12.676382,"median":-9.175503,"eighty":-7.225623,"marketCap":172744228},{"date":"2025-01-10","current":-9.541609,"twenty":-12.383498,"median":-9.381438,"eighty":-7.248561,"marketCap":175266042},{"date":"2025-01-17","current":-10.822976,"twenty":-11.486541,"median":-9.518727,"eighty":-7.460742,"marketCap":198802968},{"date":"2025-01-24","current":-10.571279,"twenty":-11.170776,"median":-9.724661,"eighty":-7.521761,"marketCap":194179644},{"date":"2025-01-31","current":-11.325839,"twenty":-11.2987,"median":-9.861951,"eighty":-7.544431,"marketCap":208039858},{"date":"2025-02-07","current":-10.266919,"twenty":-11.2987,"median":-10.022121,"eighty":-7.555364,"marketCap":188588977},{"date":"2025-02-14","current":-10.552406,"twenty":-11.252498,"median":-10.136529,"eighty":-7.621338,"marketCap":193832969},{"date":"2025-02-21","current":-7.603262,"twenty":-11.206135,"median":-9.999239,"eighty":-7.574523,"marketCap":139661309},{"date":"2025-02-28","current":-5.806127,"twenty":-11.137841,"median":-9.861951,"eighty":-7.518625,"marketCap":106650454},{"date":"2025-03-07","current":-4.700198,"twenty":-11.042639,"median":-9.689249,"eighty":-7.174012,"marketCap":86336082},{"date":"2025-03-14","current":-4.561957,"twenty":-10.951113,"median":-9.541609,"eighty":-7.036381,"marketCap":83796785},{"date":"2025-03-21","current":-9.216075,"twenty":-10.928231,"median":-9.438641,"eighty":-6.704264,"marketCap":169286436},{"date":"2025-03-28","current":-8.340548,"twenty":-10.90535,"median":-9.216075,"eighty":-6.852872,"marketCap":153204224},{"date":"2025-04-04","current":-6.636447,"twenty":-10.864163,"median":-9.011547,"eighty":-6.704264,"marketCap":143893470},{"date":"2025-04-11","current":-7.796363,"twenty":-10.722297,"median":-8.730961,"eighty":-6.759947,"marketCap":169043136},{"date":"2025-04-17","current":-8.340296,"twenty":-10.567504,"median":-8.501461,"eighty":-6.795924,"marketCap":180836843},{"date":"2025-04-25","current":-8.521606,"twenty":-10.542452,"median":-8.46117,"eighty":-6.852364,"marketCap":184768079},{"date":"2025-05-02","current":-7.8568,"twenty":-10.498764,"median":-8.409668,"eighty":-7.030646,"marketCap":170353548},{"date":"2025-05-09","current":-7.917237,"twenty":-10.46885,"median":-8.350494,"eighty":-7.05932,"marketCap":171663960},{"date":"2025-05-16","current":-7.735926,"twenty":-10.401955,"median":-8.271427,"eighty":-7.082258,"marketCap":167732724},{"date":"2025-05-23","current":-5.593729,"twenty":-10.356677,"median":-8.259713,"eighty":-7.009861,"marketCap":131477994},{"date":"2025-05-30","current":-5.909654,"twenty":-10.322004,"median":-8.210864,"eighty":-6.792598,"marketCap":138903659},{"date":"2025-06-06","current":-5.370723,"twenty":-10.312959,"median":-8.038111,"eighty":-6.609295,"marketCap":126236344}],"updateTime":1749289547806}}}